NervGen Pharma Corp: Trading Resumes After Temporary Halt
Vancouver, BC, May 23, 2025 — NervGen Pharma Corp, a biotech company specializing in the development of drugs for spinal cord injury, multiple sclerosis, Alzheimer’s disease, nerve damage, and neurodegenerative diseases, experienced a temporary trading halt on the TSX Venture Exchange. The halt, initiated by the Canadian Investment Regulatory Organization (CIRO) at 10:13 AM ET due to a single stock circuit breaker, was lifted at 10:18 AM ET, allowing trading to resume.
The trading halt came shortly after the company announced it would present topline data for its NVG-291 Phase 1b/2a chronic cohort study at the American Spinal Injury Association Annual Scientific Meeting. This announcement had previously contributed to a surge in the company’s stock price, reaching a 52-week high of $5.60 on May 21, 2025, as reported by Bay Street.
NervGen Pharma Corp, listed on the TSX Venture Exchange with a market capitalization of approximately 284.9 million CAD, saw its share price close at 6.57 CAD on May 20, 2025. The company’s stock has experienced significant volatility, with a 52-week range between 1.65 CAD and 7.05 CAD.
The temporary halt and subsequent resumption of trading highlight the market’s sensitivity to news and developments within the biotech sector, particularly for companies like NervGen Pharma Corp that are at the forefront of innovative treatments for challenging medical conditions.
For more information, visit NervGen Pharma Corp’s website .